Soares Karen sold $233K of CLOV

Soares Karen (Chief Legal Officer) sold 51,700 shares of CLOVER HEALTH INVESTMENTS, CORP. /DE (CLOV) at $4.51 ($0.23M total) on 2026-07-20 under a Rule 10b5-1 trading plan.

Original reporting
SEC EDGAR · Soares Karen
Published Jul 20, 2026, 9:48 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Jul 20, 2026, 9:52 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefInsider activity
Primary signal
$CLOV
Neutral
medium confidence
Mentioned
$CLOV
Relevance
3/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$CLOVNeutralLow
01

Why it matters

The disclosure provides incremental information about insider liquidity and planned selling, but it does not include new business, regulatory, or financial developments.

02

Market read

Traders may treat this as a low-signal datapoint for sentiment, not a standalone catalyst.

03

What to watch

The presence of a 10b5-1 plan means the sale timing is pre-set, which can weaken the signal-to-noise for interpreting bearish intent.

Relevance 3/10Novelty 5/10Timing: Filed same day as the 2026-07-20 sale date.

Background

The filing is an SEC Form 4 insider transaction by CLOV’s Chief Legal Officer, reported as an open-market sale under a Rule 10b5-1 plan.

Company-level read

Ticker impact

$CLOVNeutralMedium confidence
Context

Clover Health CLOV disclosed an officer open-market sale of 51,700 shares at $4.51 on 2026-07-20 under a 10b5-1 plan.

Expected impact

Limited near-term impact; any reaction is likely muted unless paired with other new company-specific news.

Evidence & confidence

Form 4 shows an officer sale (not a purchase) and includes a pre-arranged 10b5-1 plan, which typically reduces interpretive weight versus discretionary selling.

Market effects

No direct sector read-through; this is company-specific insider transaction disclosure.

None indicated.

None indicated.

Counterpoint

Insider selling can still coincide with near-term risk perception, so traders may watch for follow-on disclosures or changes in trading patterns.

Key entities

  • Clover Health Investments, Corp. /DE

    Subject of the Form 4 insider transaction disclosure.

  • Soares Karen

    Chief Legal Officer who sold 51,700 shares at $4.51 on 2026-07-20 under a 10b5-1 plan.

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

Related articles

$UNHMed

Medicare, Medicaid Overhaul Targets Fraudulent Billing and Unauthorized Marketplace Enrollments

CMS proposed reforms to combat fraud in Medicare, Medicaid, CHIP, and the Health Insurance Marketplace, aiming to save $90B over 10 years. The rule strengthens oversight, requires self-reporting of overpayments, and increases transparency. Managed care stocks fell, including UNH, HUM, CVS, CLOV, CNC, MOH, ELV, and OSCR. Medicare anti-fraud efforts saved $41.9B in 2025, with a $22.30 return per dollar spent.

$HUMHighAI 9/10

Humana (HUM) Stock Hits New 52-Week High

Humana (HUM) reached a new 52-week high after reporting Q3 2026 earnings with a smaller loss and raised full-year EPS guidance. Competitors like CVS Health and Elevance Health also saw gains. Clover Health (CLOV) reported Q3 2026 earnings with a slight profit and raised full-year targets.

$CLOVHighAI 8/10

Clover Health (CLOV) Q3 2026 Earnings Call Transcript

Clover Health (CLOV) reported Q3 2026 earnings, highlighting 49% YoY membership growth to 157,000 members, 57% revenue increase to $2.3B, and doubled adjusted EBITDA to $97M. The company achieved high Star Ratings for its plans and improved HEDIS quality performance. Clover Assistant's engagement accelerated, driving better care and economics. The board appointed Clay Thornton as permanent CFO. Management expects continued growth and profitability in 2027 and 2028.